Junzheng Wu
Research Subjects
Junzheng Wu has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Xiaoming Yang
National Engineering Technology Research Center for Combined Vaccines, Wuhan, China
5 shared publications Daoxing Fu
Beijing Tiantan Biological Products CO., Ltd., Beijing, China
4 shared publicationsDongbo Zhou
Beijing Tiantan Biological Products CO., Ltd., Beijing, China
4 shared publicationsHong Liang
Beijing Tiantan Biological Products CO., Ltd., Beijing, China
4 shared publicationsHuanhuan Guo
Wuxue Wusheng Plasma Collection Center, Wuxue, China
4 shared publicationsHuichuan Yang
China National Biotec Group Company Ltd Beijing China
4 shared publications
Latest Publications
- Open Access
Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is capable of large‐scale transmission and has caused the coronavirus disease 2019 (COVID‐19) pandemic. Patients with COVID‐19 may experience persistent long‐term health issues, known as long COVID. Both acute SARS‐CoV‐2 infection and long COVID have resulted in persistent negative impacts on global public health. The effective application and development of blood‐derived products are important strategies to combat the serious damage caused by COVID‐19. Since the emergence of COVID‐19, various blood‐derived products that target or do not target SARS‐CoV‐2 have been investigated for therapeutic applications. SARS‐CoV‐2‐targeting blood‐derived products, including COVID‐19 convalescent plasma, COVID‐19 hyperimmune globulin, and recombinant anti‐SARS‐CoV‐2 neutralizing immunoglobulin G, are virus‐targeting and can provide immediate control of viral infection in the short term. Non‐SARS‐CoV‐2‐targeting blood‐derived products, including intravenous immunoglobulin and human serum albumin exhibit anti‐inflammatory, immunomodulatory, antioxidant, and anticoagulatory properties. Rational use of these products can be beneficial to patients with SARS‐CoV‐2 infection or long COVID. With evidence accumulated since the pandemic began, we here summarize the progress of blood‐derived product therapies for COVID‐19, discuss the effective methods and scenarios regarding these therapies, and provide guidance and suggestions for clinical treatment.
Open AccessBlood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is capable of large‐scale transmission and has caused the coronavirus disease 2019 (COVID‐19) pandemic. Patients with COVID‐19 may experience persistent long‐term health issues, known as long COVID. Both acute SARS‐CoV‐2 infection and long COVID have resulted in persistent negative impacts on global public health. The effective application and development of blood‐derived products are important strategies to combat the serious damage caused by COVID‐19. Since the emergence of COVID‐19, various blood‐derived products that target or do not target SARS‐CoV‐2 have been investigated for therapeutic applications. SARS‐CoV‐2‐targeting blood‐derived products, including COVID‐19 convalescent plasma, COVID‐19 hyperimmune globulin, and recombinant anti‐SARS‐CoV‐2 neutralizing immunoglobulin G, are virus‐targeting and can provide immediate control of viral infection in the short term. Non‐SARS‐CoV‐2‐targeting blood‐derived products, including intravenous immunoglobulin and human serum albumin exhibit anti‐inflammatory, immunomodulatory, antioxidant, and anticoagulatory properties. Rational use of these products can be beneficial to patients with SARS‐CoV‐2 infection or long COVID. With evidence accumulated since the pandemic began, we here summarize the progress of blood‐derived product therapies for COVID‐19, discuss the effective methods and scenarios regarding these therapies, and provide guidance and suggestions for clinical treatment.
- 5 August 2023
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal
- Vol. 44 (1) , 20-25
Novel “Z” Technique to Overcome Warping of Costal Cartilage
Dorsal augmentation with costal cartilage is generally used for aesthetic rhinoplasty. However, the warping tendency of costal cartilage may jeopardize the aesthetic results of rhinoplasty. Describing a new “Z” technique to overcome the warping of costal cartilage after implantation and evaluating its efficacy in vitro. A total of 31 pairs of porcine costal cartilage grafts (40 × 10 × 5 mm) were obtained and kept in Dulbecco’s Modified Eagle Medium to maintain cell viability. Paired grafts were obtained and randomly allocated for preparation by the accordion technique and the Z technique. Standardized photographs (obtained immediately after operation and at 4 weeks) were used for warping analysis. Biomechanical test was performed to measure the graft’s capacity to resist deformation by an external force. Cell viability of the grafts at 4 weeks was comparably good in the Accordion group and the Z group (61.88% ± 4.47% vs. 67.48% ± 7.03%, P = 0.55). Warping angle was comparable between the two groups (P > 0.01). The capacity to resist external force was significantly better in the Z group; the force needed to cause deformation was 3.98 ± 1.04 N in the Z group vs. 1.61 ± 0.47 N in the Accordion group in the lateral views (P < 0.0001), and 1.33 ± 0.41 N vs. 0.96 ± 0.24 N, respectively, in the frontal views (P = 0.0013). The “Z” technique appears to be a simple and effective method to minimize warping tendency of costal cartilage after implantation.
- 5 August 2023
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal
- Vol. 44 (1) , 20-25
Novel “Z” Technique to Overcome Warping of Costal Cartilage
Dorsal augmentation with costal cartilage is generally used for aesthetic rhinoplasty. However, the warping tendency of costal cartilage may jeopardize the aesthetic results of rhinoplasty. Describing a new “Z” technique to overcome the warping of costal cartilage after implantation and evaluating its efficacy in vitro. A total of 31 pairs of porcine costal cartilage grafts (40 × 10 × 5 mm) were obtained and kept in Dulbecco’s Modified Eagle Medium to maintain cell viability. Paired grafts were obtained and randomly allocated for preparation by the accordion technique and the Z technique. Standardized photographs (obtained immediately after operation and at 4 weeks) were used for warping analysis. Biomechanical test was performed to measure the graft’s capacity to resist deformation by an external force. Cell viability of the grafts at 4 weeks was comparably good in the Accordion group and the Z group (61.88% ± 4.47% vs. 67.48% ± 7.03%, P = 0.55). Warping angle was comparable between the two groups (P > 0.01). The capacity to resist external force was significantly better in the Z group; the force needed to cause deformation was 3.98 ± 1.04 N in the Z group vs. 1.61 ± 0.47 N in the Accordion group in the lateral views (P < 0.0001), and 1.33 ± 0.41 N vs. 0.96 ± 0.24 N, respectively, in the frontal views (P = 0.0013). The “Z” technique appears to be a simple and effective method to minimize warping tendency of costal cartilage after implantation.
- Open Access
- 9 December 2022
- Published by Springer Nature in Cell Discovery
- Vol. 8 (1) , 1-14
COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan
The immunity of patients who recover from coronavirus disease 2019 (COVID-19) could be long lasting but persist at a lower level. Thus, recovered patients still need to be vaccinated to prevent reinfection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or its mutated variants. Here, we report that the inactivated COVID-19 vaccine can stimulate immunity in recovered patients to maintain high levels of anti-receptor-binding domain (RBD) and anti-nucleocapsid protein (NP) antibody titers within 9 months, and high neutralizing activity against the prototype, Delta, and Omicron strains was observed. Nevertheless, the antibody response decreased over time, and the Omicron variant exhibited more pronounced resistance to neutralization than the prototype and Delta strains. Moreover, the intensity of the SARS-CoV-2-specific CD4+ T cell response was also increased in recovered patients who received COVID-19 vaccines. Overall, the repeated antigen exposure provided by inactivated COVID-19 vaccination greatly boosted both the potency and breadth of the humoral and cellular immune responses against SARS-CoV-2, effectively protecting recovered individuals from reinfection by circulating SARS-CoV-2 and its variants.
- 9 December 2022
- Published by Springer Nature in Cell Discovery
- Vol. 8 (1) , 1-14
Open AccessCOVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan
The immunity of patients who recover from coronavirus disease 2019 (COVID-19) could be long lasting but persist at a lower level. Thus, recovered patients still need to be vaccinated to prevent reinfection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or its mutated variants. Here, we report that the inactivated COVID-19 vaccine can stimulate immunity in recovered patients to maintain high levels of anti-receptor-binding domain (RBD) and anti-nucleocapsid protein (NP) antibody titers within 9 months, and high neutralizing activity against the prototype, Delta, and Omicron strains was observed. Nevertheless, the antibody response decreased over time, and the Omicron variant exhibited more pronounced resistance to neutralization than the prototype and Delta strains. Moreover, the intensity of the SARS-CoV-2-specific CD4+ T cell response was also increased in recovered patients who received COVID-19 vaccines. Overall, the repeated antigen exposure provided by inactivated COVID-19 vaccination greatly boosted both the potency and breadth of the humoral and cellular immune responses against SARS-CoV-2, effectively protecting recovered individuals from reinfection by circulating SARS-CoV-2 and its variants.
- 5 December 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 640, 80-87
Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model
- 5 December 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 640, 80-87
Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model
- Open Access
- 5 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1
Author Correction: Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
- 5 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1
Open AccessAuthor Correction: Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
- Open Access
- 6 July 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-9
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 35.7% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.
- 6 July 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-9
Open AccessTwelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 35.7% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.
- Open Access
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 64.3% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.
Open AccessTwelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 64.3% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.